In recent trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 0.37 million shares changing hands at last check today with its beta currently measuring 0.68. Company’s recent per share price level of $1.02 trading at $0.01 or 1.17% at last check today assigns it a market valuation of $202.52M. That most recent trading price of ESPR’s stock is at a discount of -286.27% from its 52-week high price of $3.94 and is indicating a premium of 32.35% from its 52-week low price of $0.69. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.86 million shares which gives us an average trading volume of 5.19 million if we extend that period to 3-months.
For Esperion Therapeutics Inc (ESPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.88. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Upright in the green today for gaining 1.17%, in the last five days ESPR remained trading in the red while hitting it’s week-highest on Friday, 06/20/25 when the stock touched $1.02 price level, adding 8.93% to its value on the day. Esperion Therapeutics Inc’s shares saw a change of -53.13% in year-to-date performance and have moved -7.11% in past 5-day. Esperion Therapeutics Inc (NASDAQ:ESPR) showed a performance of 24.62% in past 30-days. Number of shares sold short was 24.11 million shares which calculate 4.98 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 91.5% to its recent value today. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -684.31% in reaching the projected high whereas dropping to the targeted low would mean a loss of -684.31% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 40.11% during past 5 years.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
Insiders are in possession of 0.57% of company’s total shares while institution are holding 59.30 percent of that, with stock having share float percentage of 59.65%. Investors also watch the number of corporate investors in a company very closely, which is 59.30% institutions for Esperion Therapeutics Inc that are currently holding shares of the company. WASATCH ADVISORS LP is the top institutional holder at ESPR for having 16.86 million shares of worth $37.44 million. And as of 2024-06-30, it was holding 8.9319 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 13.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4068 of outstanding shares, having a total worth of $31.04 million.
On the other hand, WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 6.68 shares of worth $6.91 million or 3.37% of the total outstanding shares. The later fund manager was in possession of 6.18 shares on Mar 31, 2025 , making its stake of worth around $6.4 million in the company or a holder of 3.12% of company’s stock.
